IS6291A - Lausn sem inniheldur galantamín og sætuefni, til inntöku um munn - Google Patents

Lausn sem inniheldur galantamín og sætuefni, til inntöku um munn

Info

Publication number
IS6291A
IS6291A IS6291A IS6291A IS6291A IS 6291 A IS6291 A IS 6291A IS 6291 A IS6291 A IS 6291A IS 6291 A IS6291 A IS 6291A IS 6291 A IS6291 A IS 6291A
Authority
IS
Iceland
Prior art keywords
sweetener
solution containing
oral solution
containing galantamine
galantamine
Prior art date
Application number
IS6291A
Other languages
English (en)
Other versions
IS2628B (is
Inventor
Karel Jozef Francois Marc
Mathilde Jozef Kempen Tony
André Josée De Proost Eddy
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of IS6291A publication Critical patent/IS6291A/is
Publication of IS2628B publication Critical patent/IS2628B/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
IS6291A 1999-10-26 2002-02-28 Lausn til inntöku sem inniheldur galantamín og sætumiðil IS2628B (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99203512 1999-10-26
PCT/EP2000/010203 WO2001030318A1 (en) 1999-10-26 2000-10-16 Oral solution containing galanthamine and a sweetening agent

Publications (2)

Publication Number Publication Date
IS6291A true IS6291A (is) 2002-02-28
IS2628B IS2628B (is) 2010-05-15

Family

ID=8240778

Family Applications (1)

Application Number Title Priority Date Filing Date
IS6291A IS2628B (is) 1999-10-26 2002-02-28 Lausn til inntöku sem inniheldur galantamín og sætumiðil

Country Status (30)

Country Link
EP (1) EP1237539B1 (is)
JP (1) JP2003512415A (is)
KR (1) KR100502391B1 (is)
CN (1) CN1200691C (is)
AR (1) AR026243A1 (is)
AT (1) ATE306904T1 (is)
AU (1) AU780826C (is)
BG (1) BG65792B1 (is)
BR (1) BR0015025A (is)
CA (1) CA2388830C (is)
CZ (1) CZ301996B6 (is)
DE (1) DE60023341T2 (is)
DK (1) DK1237539T3 (is)
EA (1) EA005683B1 (is)
EE (1) EE05230B1 (is)
ES (1) ES2250211T3 (is)
HK (1) HK1049619A1 (is)
HR (1) HRP20020332B1 (is)
HU (1) HUP0203484A3 (is)
IL (2) IL149310A0 (is)
IS (1) IS2628B (is)
MX (1) MXPA02004149A (is)
NO (1) NO332096B1 (is)
PL (1) PL201694B1 (is)
SI (1) SI1237539T1 (is)
SK (1) SK285643B6 (is)
TW (1) TW592725B (is)
UA (1) UA76095C2 (is)
WO (1) WO2001030318A1 (is)
ZA (1) ZA200203313B (is)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030162770A1 (en) * 2002-02-22 2003-08-28 Davis Bonnie M. Use of modulators of nicotinic receptors for treatment of cognitive dysfunction
US7297691B2 (en) 2003-08-13 2007-11-20 Janssen Pharmaceutica N.V. Treatment of sleep disorders with cholinesterase inhibitors
US20050191349A1 (en) * 2003-12-31 2005-09-01 Garth Boehm Galantamine formulations
US8709521B2 (en) * 2007-05-22 2014-04-29 The Coca-Cola Company Sweetener compositions having enhanced sweetness and improved temporal and/or flavor profiles
AU2012209466C1 (en) * 2011-01-27 2016-06-23 Neuren Pharmaceuticals Limited Treatment of Autism Spectrum Disorders using Glycyl-L-2-Methylprolyl-L-Glutamic Acid
US20140107130A1 (en) * 2012-10-11 2014-04-17 Antrim Pharmaceuticals, LLC Oral Solution Formulations of Aripiprazole
JP6457582B2 (ja) * 2017-04-14 2019-01-23 エルメッド エーザイ株式会社 ガランタミン含有医薬組成物、並びに医薬組成物におけるガランタミンの苦味抑制方法、及びガランタミンの苦味抑制剤

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4010079A1 (de) * 1990-03-29 1991-10-02 Lohmann Therapie Syst Lts Pharmazeutische formulierung zur behandlung des alkoholismus
US5272137A (en) * 1992-02-14 1993-12-21 Mcneil-Pfc, Inc. Aqueous pharmaceutical suspension for pharmaceutical actives
US6323195B1 (en) * 1993-10-15 2001-11-27 Aventis Pharmaceuticals Inc. Galanthamine derivatives as acetylcholinesterase inhibitors
JPH10273435A (ja) * 1997-01-29 1998-10-13 Fujisawa Pharmaceut Co Ltd 内服用液剤

Also Published As

Publication number Publication date
ATE306904T1 (de) 2005-11-15
HK1049619A1 (en) 2003-05-23
HRP20020332A2 (en) 2004-02-29
UA76095C2 (en) 2006-07-17
HUP0203484A3 (en) 2004-12-28
KR100502391B1 (ko) 2005-07-19
NO20022003D0 (no) 2002-04-26
IL149310A0 (en) 2002-11-10
AU780826B2 (en) 2005-04-21
EP1237539A1 (en) 2002-09-11
AR026243A1 (es) 2003-02-05
EP1237539B1 (en) 2005-10-19
CZ301996B6 (cs) 2010-09-01
CN1200691C (zh) 2005-05-11
ZA200203313B (en) 2003-11-26
PL362849A1 (en) 2004-11-02
ES2250211T3 (es) 2006-04-16
AU780826C (en) 2006-02-16
SK5302002A3 (en) 2002-10-08
EE200200213A (et) 2003-06-16
SK285643B6 (sk) 2007-05-03
NO20022003L (no) 2002-06-18
BG65792B1 (bg) 2009-12-31
CA2388830A1 (en) 2001-05-03
PL201694B1 (pl) 2009-04-30
TW592725B (en) 2004-06-21
SI1237539T1 (sl) 2006-04-30
KR20020026010A (ko) 2002-04-04
DK1237539T3 (da) 2006-02-27
CA2388830C (en) 2006-09-19
EA200200486A1 (ru) 2002-10-31
AU1384901A (en) 2001-05-08
CZ20021329A3 (cs) 2002-08-14
DE60023341T2 (de) 2006-07-27
WO2001030318A1 (en) 2001-05-03
IS2628B (is) 2010-05-15
EE05230B1 (et) 2009-12-15
BR0015025A (pt) 2002-06-18
CN1382037A (zh) 2002-11-27
BG106534A (en) 2002-12-29
HUP0203484A2 (hu) 2003-02-28
JP2003512415A (ja) 2003-04-02
NO332096B1 (no) 2012-06-18
EA005683B1 (ru) 2005-04-28
HRP20020332B1 (en) 2011-02-28
MXPA02004149A (es) 2002-10-17
DE60023341D1 (de) 2006-03-02
IL149310A (en) 2006-12-10

Similar Documents

Publication Publication Date Title
IS6263A (is) Lyfjasamsetningar, sem innihalda trípeptíð
ZA200202480B (en) Oral dosage forms.
HUP0203204A3 (en) Oral dosage forms
TR200003788A3 (tr) Yavas salimli oral dozaj bilesim.
DK1233943T3 (da) Ioniserbare indolinon derivater og anvendelse deraf som PTK ligander
NO20021379D0 (no) Benzodiazepin-derivater, fremstilling og anvendelse derav
NO20012567D0 (no) Azepinoindolderivater, fremstilling og anvendelse derav
DK1180518T3 (da) 5-pyridyl-1,3-azolforbindelser, fremgangsmåde til fremstilling deraf og anvendelse deraf
NO20011216L (no) Azetidinderivater, deres fremstilling og medikamenter inneholdende forbindelsene
ZA200007715B (en) Stable extended release oral dosage composition.
GB9930322D0 (en) Rotating membrane
NO20006138L (no) Substituerte indolinoner, fremstilling og anvendelse derav som medikamenter
ZA200203003B (en) N-substituted carbamoyloxyalkyl-azolium derivatives.
HU9901830D0 (en) Nefazodone dosage form
ATE257159T1 (de) Oral wirksame androgene
EP1223175A4 (en) SOLID AND LIQUID SWEETENER COMPOSITIONS AND THEIR USE
IS2821B (is) Amínóalkýlbensóýl-bensófúran eða bensóþíófenafleiður, aðferð til framleiðslu þeirra og samsetningar sem innihalda þær
DK1057813T3 (da) Indolderivater og medicinske sammensætninger indeholdende de samme
MXPA03000644A (es) Nuevos derivados de indol y uso como medicamentos.
HK1046528A1 (en) 4-Phenyl-pyrimidine derivatives 4-.
GB9902687D0 (en) Cryptographic protocol
IS6291A (is) Lausn sem inniheldur galantamín og sætuefni, til inntöku um munn
ATE246502T1 (de) Arzneiformen enthaltend carvedilol
ID30397A (id) Larutan oral prukaloprida
NO20014853L (no) Smakstilsetning